

To,
Head, Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001.

Head, Listing Compliance
Department National Stock Exchange
of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051.

Scrip Code: 542650

Scrip Symbol: METROPOLIS

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the company would like to update on the following key business parameters of the Company for the quarter ended June 30, 2023:

1. Core business* revenue growth for Q1FY24 stood at ~12% *on Y-o-Y* basis. Total Revenue from operations for Q1FY24 stood marginally negative as compared to Q1FY23, mainly due to covid and B2G contract. It should be noted that a sizeable B2G contract was in-sourced by Government in Q4FY23.
2. For companies with larger market share in West India, Q1 is seasonally the weakest quarter due to summer holidays. Like pre-covid years, lower revenue growth in Q1 with marginal cost increase on Y-o-Y basis impacts the operating margins causing the quarter to have the lowest margin amongst all quarters in a financial year.

Q1FY24 saw seasonal impact on margins which was further accentuated by in-source of B2G business which resulted in lower margins. The company expects the margin trajectory to improve in rest of the financial year.
3. Core business* volume growth for Q1FY24 stood at ~13% on Y-o-Y basis
4. Revenue per test (Core Business1) for Q1FY24 was up by 3% on Y-o-Y basis
5. Revenue per patient (Core Business1) for Q1FY24 stood flat on account of expiration of B2G contract
6. B2C revenue growth stood at ~12% on Y-o-Y basis

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited
Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.
CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com
Website: www.metropolisindia.com
Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W),
Mumbai - 400 070.

7. Premium wellness segment grew by ~23% on Y-o-Y basis

8. Gross Debt as on 30th June, 2023 stood at Rs. 67 Crs.

*Excludes revenue from Covid & Covid Allied tests & PPP Contracts; including Hi-Tech

The above information is on a Consolidated basis and subject to a limited review by the Management Team. The Company will continue to provide the above update at the end of every quarter for the current financial year.

Thanking You.

Yours faithfully

For **Metropolis Healthcare Limited**

Neha Shah
**Interim Company Secretary &
Compliance Officer**
ACS No. A51465

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.